GoodRx price target raised to $7.50 from $6 at Wells Fargo

Wells Fargo analyst Stan Berenshteyn raised the firm’s price target on GoodRx to $7.50 from $6 and keeps an Equal Weight rating on the shares. GoodRx appears to be finding its footing, but strategy pivots have lowered long-term growth visibility, limiting the firm’s ability to build a case for outperformance, the analyst tells investors in a research note.